These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31115229)

  • 1. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias.
    De Riva V; Galloni E; Lealini B; Zarantonello G; Disco C; Dionisio LD; Meligrana L; Marcon M; Perini F
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of combined CSF biomarkers in AD diagnosis.
    De Riva V; Galloni E; Marcon M; Di Dionisio L; Deluca C; Meligrana L; Bolner A; Perini F
    Clin Lab; 2014; 60(4):629-34. PubMed ID: 24779297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
    Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
    J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease.
    Inekci D; Henriksen K; Linemann T; Karsdal MA; Habib A; Bisgaard C; Eriksen FB; Vilholm OJ
    Curr Alzheimer Res; 2015; 12(9):829-36. PubMed ID: 26159200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No added diagnostic value of non-phosphorylated tau fraction (p-tau
    Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary Aβ
    Fan Z; Li Z; Zhao S; Chen Y; Su Y; Peng G; Luo B
    J Neurol; 2023 Apr; 270(4):1945-1954. PubMed ID: 36562850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau.
    Liu Z; Kameshima N; Nanjo T; Shiino A; Kato T; Shimizu S; Shimizu T; Tanaka S; Miura K; Tooyama I
    J Alzheimers Dis; 2018; 62(2):737-744. PubMed ID: 29480194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
    Ewers M; Mattsson N; Minthon L; Molinuevo JL; Antonell A; Popp J; Jessen F; Herukka SK; Soininen H; Maetzler W; Leyhe T; Bürger K; Taniguchi M; Urakami K; Lista S; Dubois B; Blennow K; Hampel H
    Alzheimers Dement; 2015 Nov; 11(11):1306-15. PubMed ID: 25804998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.